Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01894451 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
A Early Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT01894451 is a Early Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 2 participants.
The verdict
NCT01894451, a Early Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This research study is a pilot study, which tests the ability of an investigational compound to be used in humans for further studies. "Investigational" means that 89Zr-bevacizumab for PET/CT imaging is being studied. It also means that the FDA (U.S. Food and Drug Administration) has not approved 89Zr-bevacizumab for PET/CT imaging for use in patients, including people with your type of cancer. 89Zr-bevacizumab is a newly developed radiotracer. Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance. The amount of the compound or drug in a radiotracer is also very small. Radiotracers are used to make images of processes that are happening in the body, but they do not affect how the body works. 89Zr-bevacizumab is made up of the drug bevacizumab and the radioactive substance zirconium-89 (89Zr). 89Zr-bevacizumab is used for an imaging procedure called positron emission tomography/computed tomography (PET/CT). This radiotracer has been used in other research studies. Information from those other research studies suggests that 89Zr-bevacizumab-PET/CT imaging may be able to measure new blood vessel formation to determine where the cancer is in your body and if your cancer is being killed by chemotherapy.
Interventions
- PROCEDURE MRI scan
- PROCEDURE FDG-PET/CT
- DRUG 89Zr-bevacizumab
- PROCEDURE Tumor biopsies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-03-17 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01894451
The ClinicalTrials.gov registry entry for NCT01894451 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MRI scan is the first listed.
NCT01894451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01894451 about?
NCT01894451 is a clinical study titled "Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy". This research study is a pilot study, which tests the ability of an investigational compound to be used in humans for further studies. "Investigational" means that 89Zr-bevacizumab for PET/CT imaging is being studied. It also means that the FDA (U.S. Food and Drug Administration) has not approved 89...
What is the current status of trial NCT01894451?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2015-06. Estimated completion is 2017-03-17.
What interventions are being tested in trial NCT01894451?
The interventions under investigation include: MRI scan (PROCEDURE), FDG-PET/CT (PROCEDURE), 89Zr-bevacizumab (DRUG), Tumor biopsies (PROCEDURE).
Who is sponsoring clinical trial NCT01894451?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.